MBX Biosciences Management
Management criteria checks 2/4
MBX Biosciences' CEO is Peter Hawryluk, appointed in Jan 2020, has a tenure of 6.75 years. total yearly compensation is $2.24M, comprised of 21.6% salary and 78.4% bonuses, including company stock and options. directly owns 2.52% of the company’s shares, worth $36.86M. The average tenure of the management team and the board of directors is 1.5 years and 1.9 years respectively.
Key information
Peter Hawryluk
Chief executive officer
US$2.2m
Total compensation
| CEO salary percentage | 21.62% |
| CEO tenure | 6yrs |
| CEO ownership | 2.5% |
| Management average tenure | 1.5yrs |
| Board average tenure | 1.9yrs |
Recent management updates
Recent updates
MBX Biosciences Looks A Buy As Hypoparathyroidism Data Wows Market
Sep 22Companies Like MBX Biosciences (NASDAQ:MBX) Are In A Position To Invest In Growth
Jun 28
We're Not Very Worried About MBX Biosciences' (NASDAQ:MBX) Cash Burn Rate
Mar 13MBX Biosciences: Decent Potential For Lead Indication, But Need More Data
Nov 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$80m |
| Jun 30 2025 | n/a | n/a | -US$77m |
| Mar 31 2025 | n/a | n/a | -US$73m |
| Dec 31 2024 | US$2m | US$483k | -US$62m |
| Sep 30 2024 | n/a | n/a | -US$55m |
| Jun 30 2024 | n/a | n/a | -US$47m |
| Mar 31 2024 | n/a | n/a | -US$39m |
| Dec 31 2023 | US$5m | US$420k | -US$33m |
Compensation vs Market: Peter's total compensation ($USD2.24M) is below average for companies of similar size in the US market ($USD5.29M).
Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.
CEO
Peter Hawryluk (56 yo)
Mr. P. Kent Hawryluk, MBA, co-founderd MBX Biosciences, Inc. and has been its President and Chief Executive Officer since January 2020 and Director since April 2019. He was Co-Founder and Chief Business Of...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 6yrs | US$2.24m | 2.52% $ 36.9m | |
| Chief Financial Officer | 3.8yrs | US$1.15m | 0% $ 0 | |
| Chief Medical Officer | 1.6yrs | US$3.26m | 0% $ 0 | |
| Executive Chairperson | less than a year | no data | 0.045% $ 651.0k | |
| Vice President of Marketing | 2.7yrs | no data | no data | |
| Chief Human Resources Officer | 2.3yrs | no data | no data | |
| Sr. Vice President of Discovery & Non-Clinical Development | 1.4yrs | no data | no data | |
| Senior VP of Pharmaceutical Development & Chemistry | less than a year | no data | no data | |
| Senior Vice President of Regulatory & Quality | less than a year | no data | no data | |
| Senior Vice President of Clinical Development | less than a year | no data | no data |
Experienced Management: MBX's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 6.8yrs | US$2.24m | 2.52% $ 36.9m | |
| Executive Chairperson | less than a year | no data | 0.045% $ 651.0k | |
| Independent Director | 5.5yrs | US$213.31k | 0% $ 0 | |
| Independent Director | 5.5yrs | US$205.75k | 0% $ 0 | |
| Member of Scientific Advisory Board | 1.6yrs | no data | no data | |
| Independent Director | 3.8yrs | US$422.26k | 0.054% $ 791.9k | |
| Member of Scientific Advisory Board | 1.6yrs | no data | no data | |
| Independent Director | 3.2yrs | US$207.06k | 0% $ 0 | |
| Independent Director | 1.9yrs | US$478.96k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 1.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.6yrs | no data | no data |
Experienced Board: MBX's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/08 16:18 |
| End of Day Share Price | 2026/01/08 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MBX Biosciences, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jonathan Wolleben | Citizens JMP Securities, LLC |
| Corinne Johnson | Goldman Sachs |
| Seamus Fernandez | Guggenheim Securities, LLC |